New drug trial aims to control rare blood disease in untreated patients
NCT ID NCT04654468
Summary
This study is testing whether the drug crovalimab can safely control paroxysmal nocturnal hemoglobinuria (PNH), a rare blood disease where the immune system destroys red blood cells. The trial includes about 50 people aged 12 and older with PNH who have never taken similar complement inhibitor medicines. Participants receive crovalimab for at least 24 weeks while researchers measure how well it controls blood cell destruction and reduces the need for blood transfusions.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Institute of Hematology and Hospital of Blood Disease
Tianjin, 300020, China
-
Tianjin Medical University General Hospital
Tianjin, 300052, China
-
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, 430022, China
-
West China Hospital, Sichuan University
Chengdu, 610041, China
Conditions
Explore the condition pages connected to this study.